• MPNRF | April 28, 2021

    This research study is by QuintilesIMS (sponsored by Incyte Corporation)
    QuintilesIMS Global Services, a worldwide consulting firm, is conducting a research study to better understand the experience of ET patients.  QuintilesIMS plans to interview patients who have been diagnosed with ET one‐on‐one over the phone. QuintilesIMS is looking for interested people to share what they have gone through since being diagnosed with ET.  
    The overall purpose of the study is to learn which symptoms of ET are the most common, and how these symptoms typically affect the lives of patients like you who live with the disease.  This understanding may help improve how the patient’s experience is accounted for in clinical trials that measure the effect of disease treatments.  It also may help patients and their families by highlighting the consequences of the disease that most need greater attention, possibly leading to the development of new programs and support services.  
    Your Involvement
    If you qualify, you will be invited to participate in a 75‐minute telephone discussion with one of QuintilesIMS’ healthcare researchers.  You will not need to do anything to prepare, other than being ready to describe what your life has been like while living with ET.  At no point before, during, or after the interview will you be contacted to purchase anything or be asked to take any medication.  You will be one of 20 patients participating in the study and your information will be kept confidential by removing any personal identifiers.
    In return for your voluntary participation in the interview, your time and effort will be compensated with a $125 Visa gift card.
    To participate, please call Michael Posey from QuintilesIMS, at 412‐973‐3162 (M-F, 9am ‐ 5pm EDT), or write to Michael will ask for your consent to participate in the study, see if you qualify, then schedule your interview.  

    Inclusion and exclusion criteria for ET research study:

    1. Patient is ≥18 years of age
    2. Patient has a current diagnosis of Essential Thrombocythemia (ET) and fulfills one of the following:
    • Patient has received hydroxyurea treatment in the past and discontinued it for any reason OR
    • Patient could not receive hydroxyurea because it was contraindicated for the patient
    1. Patient has some self‐reported disease related symptom burden
    2. Patient is physically and mentally able to participate in an 75 minute interview in English to discuss signs, symptoms, and impacts related to ET
    3. Patient is not currently participating in a research study where an investigational agent is being administered
    4. Patient has no prior treatment with any oral JAK inhibitor